Europe’s medical devices industry saw a rise of 12.50% in cross border deal activity during June 2022, when compared with the last 12-month average, led by ResMed’s $1bn acquisition of MediFox DAN Group, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 27 medical devices industry cross border deals worth $2.1bn were announced for the region in June 2022, against the 12-month average of 24 deals.
Of all the deal types, M&A saw most activity in June 2022 with 13 transactions, representing a 48.2% share for the region.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn second place was venture financing with 11 deals, followed by private equity deals with three transactions, respectively capturing a 40.7% and 11.1% share of the overall cross border deal activity for the month.
In terms of value of cross border deals, M&A was the leading category in Europe’s medical devices industry with $1.13bn, while private equity and venture financing deals totalled $837.86m and $169.15m, respectively.
Europe medical devices industry cross border deals in June 2022: Top deals
The top five medical devices cross border deals accounted for 94% of the overall value during June 2022.
The combined value of the top five medical devices cross border deals stood at $2.01bn, against the overall value of $2.1bn recorded for the month.
The top five medical devices industry cross border deals of June 2022 tracked by GlobalData were:
1) ResMed $1bn acquisition deal with MediFox DAN Group
2) The $797.86m private equity of SPT Labtech by EQT IX Fund
3) Azenta $85.5m acquisition deal with Barkey GmbHKG
4) The $80m venture financing of Proximie by Advent Life Sciences,British Patient Capital,Eight Roads Ventures,Emerson Collective,F Prime Capital,Global ventures,Maverick Ventures Israel,Minderoo Foundation,Mubadala Investment,Questa Capital Management and SoftBank Vision Fund 2
5) Fujirebio $42.15m acquisition deal with ADx NeuroSciences
